Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)

Overview

To determine the recommended phase 2 dose of chemotherapy in combination with Pembrolizumab in subjects with advanced lymphoma and determine the complete response rate.

Full Title of Study: “A Phase Ib/II Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: November 2015

Interventions

  • Drug: Pembrolizumab
  • Drug: Etoposide
  • Drug: Ifosfamide
  • Drug: Mesna
  • Drug: Carboplatin
  • Drug: Brentuximab vedotin
  • Drug: Rituximab

Arms, Groups and Cohorts

  • Active Comparator: RICE and Pembrolizumab
    • non-Hodgkin’s lymphoma patients requiring 2nd line or beyond therapy and eligible to receive RICE (rituximab, ifosfamide, carboplatin, and etoposide)
  • Active Comparator: ICE and Pembrolizumab
    • classical Hodgkin’s lymphoma requiring 2nd line or beyond therapy and eligible to receive ICE (ifosfamide, carboplatin, and etoposide)
  • Active Comparator: brentuximab vedotin and Pembrolizumab
    • classical Hodgkin’s lymphoma that have progressed after high-dose chemotherapy with autologous stem cell rescue or progressed on at least 2 lines of therapy and are eligible to receive brentuximab vedotin

Clinical Trial Outcome Measures

Primary Measures

  • Determine the recommended phase 2 dose (RP2D) of chemotherapy in combination with pembrolizumab (pembro) in subjects with advanced lymphoma and complete remission by Revised Response Criteria for Malignant Lymphoma.
    • Time Frame: up to 12 weeks

Secondary Measures

  • Frequency of grade 3 or higher treatment-related adverse events by CTCAE 4.03
    • Time Frame: up to 12 months
  • Response rate by immune-related response criteria (irRC)
    • Time Frame: 12 weeks
  • Overall survival (OS) and progression-free survival (PFS)
    • Time Frame: up to 12 months
  • Changes in number of copies of circulating tumor DNA in patients enrolled on this study
    • Time Frame: up to 12 months
  • Changes to pixel intensity identified on imaging that is done per routine practice
    • Time Frame: up to 12 weeks

Participating in This Clinical Trial

Inclusion Criteria

1. Patient at least 18 years old and has definitive histologically or cytologically confirmed: classical Hodgkin lymphoma (HL) or diffuse large B-Cell lymphoma (DLBCL) non-Hodgkin lymphoma (NHL).

2. Patient has one or more metastatic lesions >1.5 cm as defined by lymphoma response criteria by PET-CT scan. If CT scan is needed for clarification of findings on PET-CT it may be done additionally. Tumor sites that are considered measureable must not have received prior radiation therapy.

3. Patients can be enrolled only on one of the treatment arms on this trial.

4. The investigator will select the appropriate treatment arm for the patient with the following requirements: (a) Patients cannot have had prior progression or intolerance on the single agent chemotherapy and then enrolled on an arm with that same single agent chemotherapy plus pembro (b) The chemotherapy on the arm selected must be considered standard of care or listed in www.nccn.org for that cancer type.

5. Have recovered from acute toxicities of prior treatment:

  • > 3 weeks must have elapsed since receiving any investigational agent.
  • > 2 weeks must have elapsed since receiving any radiotherapy, or ≥ 3 weeks or 5 half-lives whichever is shorter for treatment with cytotoxic or biologic agents ( ≥ 6 weeks for mitomycin or nitrosoureas). Chronic treatment with non-investigational gonadotropin-releasing hormone analogs or other hormonal or supportive care is permitted.

6. Patient has adequate biological parameters as demonstrated by the following blood counts at time of screening:

7. Absolute neutrophil count (ANC) > 1000/ microliter, platelet count ≥ 75,000/ microliter, hemoglobin ≥ 9 g/dL. Subject can be given packed red blood cell transfusion.

8. Calculated creatinine clearance > 50 ml/min by Cockroft-Gault equation, total bilirubin 1.5 times the upper limit of normal (ULN) range, AST/ALT ≤ 3 times the upper limit of normal (ULN) range.

9. Thyroid stimulating hormone (TSH) within institutional normal limits. If TSH is above the upper limit of normal range, then a free T4 within institutional normal limits is acceptable.

10. At least 100 days must have elapsed in subjects that had a prior autologous transplant.

11. Resolution of prior systemic therapy non-hematologic AE to grade ≤ 2 (except alopecia or correctable electrolyte abnormality with supplementation)

12. Patient has a Karnofsky performance status (KPS) ≥ 60.

13. Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must be willing to use an acceptable contraceptive method (abstinence, oral contraceptive or double barrier method) for the duration of the study and for 4 months following the last dose of Pembrolizumab, brentuximab vedotin, or for 2 years following the last dose of chemotherapy on this trial, and must have a negative urine or serum pregnancy test within 2 weeks prior to beginning treatment on this trial. If a female subject or female partner of a male subject becomes pregnant during this period then patient will be recommended to seek appropriate obstetric care. The study will not be monitoring subjects or female partners of subjects for pregnancy after the last dose of study drug or chemotherapy.

Exclusion Criteria

1. Active clinically serious infection > Grade 2.

2. Serious non-healing wound, ulcer, or bone fracture.

3. Patient has known brain metastases.

4. Patient has with myelodysplasia, polycythemia vera, idiopathic thrombocythemia, myelofibrosis, or acute leukemia.

5. Inability to complete informed consent process and adhere to the protocol treatment plan and follow-up requirements.

6. Patient has known active infection with HIV, hepatitis B, or hepatitis C (patients will be required to be tested for the presence of such viruses prior to therapy on this protocol).

7. Ejection fraction measuring less than 45% (measurement of ejection fraction is required only for subjects with prior anthracycline exposure).

8. Requiring daily corticosteroid dose ≥ 10 mg prednisone or equivalent per day.

9. Patient has undergone major surgery, other than diagnostic surgery (e.g., surgery done to obtain a biopsy for diagnosis without removal of an organ), within 4 weeks prior to Day 1 of treatment in this study.

10. Patient has a history of allergy or hypersensitivity to any of the study drugs or any of their excipients, or the patient exhibits any of the events outlined in the Contraindication or Special Warnings and Precautions sections of the product or comparator SmPC or Prescribing Information.

11. Patient has serious medical risk factors involving any of the major organ systems, or serious psychiatric disorders, which could compromise the patient's safety or the study data integrity.

12. Patient will be receiving any other anti-cancer therapy during participation in this trial.

13. Prior treatment with Pembrolizumab is not allowed. Prior receipt of other PD-1 inhibitors or PD-L1 inhibitors is allowed.

14. Active or prior documented autoimmune disease requiring systemic treatment within the past 2 years.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Western Regional Medical Center
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.